Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
MNK's Cash to Debt is ranked lower than
97% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. MNK: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
MNK' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.23 Max: N/A
Current: 0.05
Equity to Asset 0.32
MNK's Equity to Asset is ranked lower than
87% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MNK: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
MNK' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.35 Max: 0.41
Current: 0.32
0.25
0.41
Interest Coverage 1.69
MNK's Interest Coverage is ranked lower than
88% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. MNK: 1.69 )
Ranked among companies with meaningful Interest Coverage only.
MNK' s Interest Coverage Range Over the Past 10 Years
Min: 1.81  Med: 204.30 Max: 470.4
Current: 1.69
1.81
470.4
F-Score: 6
Z-Score: 0.79
M-Score: -2.70
WACC vs ROIC
6.90%
9.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 17.13
MNK's Operating margin (%) is ranked higher than
76% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. MNK: 17.13 )
Ranked among companies with meaningful Operating margin (%) only.
MNK' s Operating margin (%) Range Over the Past 10 Years
Min: -11.18  Med: 11.44 Max: 13.8
Current: 17.13
-11.18
13.8
Net-margin (%) 13.59
MNK's Net-margin (%) is ranked higher than
76% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. MNK: 13.59 )
Ranked among companies with meaningful Net-margin (%) only.
MNK' s Net-margin (%) Range Over the Past 10 Years
Min: -12.57  Med: 6.55 Max: 9.7
Current: 13.59
-12.57
9.7
ROE (%) 8.87
MNK's ROE (%) is ranked higher than
57% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. MNK: 8.87 )
Ranked among companies with meaningful ROE (%) only.
MNK' s ROE (%) Range Over the Past 10 Years
Min: -10.28  Med: 6.32 Max: 9.37
Current: 8.87
-10.28
9.37
ROA (%) 3.04
MNK's ROA (%) is ranked lower than
55% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. MNK: 3.04 )
Ranked among companies with meaningful ROA (%) only.
MNK' s ROA (%) Range Over the Past 10 Years
Min: -3.91  Med: 2.22 Max: 3.31
Current: 3.04
-3.91
3.31
ROC (Joel Greenblatt) (%) 41.35
MNK's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. MNK: 41.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -19.54  Med: 19.35 Max: 32.13
Current: 41.35
-19.54
32.13
» MNK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MNK Guru Trades in Q2 2015

Jim Simons 151,202 sh (New)
Paul Tudor Jones 210,922 sh (+643.10%)
Joel Greenblatt 246,557 sh (+280.64%)
Andreas Halvorsen 5,415,671 sh (+53.10%)
First Eagle Investment 187 sh (unchged)
John Hussman 25,000 sh (unchged)
RS Investment Management Sold Out
Louis Moore Bacon Sold Out
Pioneer Investments 1,348,630 sh (-7.27%)
Jeremy Grantham 1,991 sh (-9.50%)
John Paulson 6,594,193 sh (-22.06%)
Mario Gabelli 4,872 sh (-31.59%)
» More
Q3 2015

MNK Guru Trades in Q3 2015

Steven Cohen 53,200 sh (New)
Jim Simons 557,902 sh (+268.98%)
John Paulson 6,594,193 sh (unchged)
First Eagle Investment 187 sh (unchged)
John Hussman 25,000 sh (unchged)
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli Sold Out
Andreas Halvorsen 3,911,692 sh (-27.77%)
Pioneer Investments 224,471 sh (-83.36%)
Joel Greenblatt 27,685 sh (-88.77%)
» More
Q4 2015

MNK Guru Trades in Q4 2015

Ken Heebner 665,000 sh (New)
Louis Moore Bacon 16,998 sh (New)
Jeremy Grantham 3,834 sh (New)
George Soros 6,500 sh (New)
Mario Gabelli 15,562 sh (New)
Paul Tudor Jones 8,097 sh (New)
David Dreman 203 sh (New)
John Paulson 8,623,693 sh (+30.78%)
First Eagle Investment 187 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Andreas Halvorsen Sold Out
John Hussman Sold Out
Joel Greenblatt Sold Out
Pioneer Investments Sold Out
» More
Q1 2016

MNK Guru Trades in Q1 2016

Joel Greenblatt 580,887 sh (New)
David Dreman 4,027 sh (+1883.74%)
Ken Heebner 1,125,000 sh (+69.17%)
John Paulson 8,949,380 sh (+3.78%)
First Eagle Investment 187 sh (unchged)
Louis Moore Bacon Sold Out
Jeremy Grantham Sold Out
George Soros Sold Out
Paul Tudor Jones 7,622 sh (-5.87%)
Mario Gabelli 14,562 sh (-6.43%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OCSE:LUN, TSE:4581, BOM:524804, SHSE:600196, OSTO:MEDA A » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents.

Mallinckrodt PLC was incorporated in Ireland on January 9, 2013. The Company along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents. Its therapeutic areas of focus include autoimmune and rare disease specialty areas (including neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; pain management; and central nervous system drugs. It also supports the diagnosis of disease with nuclear medicine imaging agents. The Company operates in three segments including Specialty Brands, Specialty Generics, and Nuclear Imaging. Specialty Brands segment produces and markets branded pharmaceuticals and biopharmaceuticals products for autoimmune and rare diseases (including in the specialty areas of neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; and central nervous system drugs. Its Specialty Brands product portfolio includes Acthar an injectable biopharmaceutical drug; Ofirmev a proprietary intravenous formulation of acetaminophen indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever; Inomax a vasodilator that, in conjunction with ventilatory support and other appropriate agents, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension; Therakos immunotherapy provides immunotherapy treatment platforms that enhance the ability of a patient's immune system to fight disease; and Exalgo a long-acting, once-daily form of hydromorphone. Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Specialty Generics product portfolio includes hydrocodone (API) and hydrocodone-containing tablets; hydrocodone (API) and hydrocodone-containing tablets; methylphenidate HCl extended-release tablets USP (CII); and other controlled substances, including acetaminophen (API) products. Nuclear Imaging segment develops, manufactures and markets products which provide radiopharmaceuticals used in single photon emission computed tomography ("SPECT") imaging for myocardial perfusion, cardiac imaging and bone scans. Its Nuclear Imaging business manufactures radioactive isotopes for the diagnosis and treatment of disease. Its nuclear radiopharmaceutical product offering includes both hot radioisotopes and cold kits. The Nuclear Imaging product portfolio includes Ultra-Technekow DTE a dry-ship, top

Ratios

vs
industry
vs
history
P/E(ttm) 15.34
MNK's P/E(ttm) is ranked higher than
77% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. MNK: 15.34 )
Ranked among companies with meaningful P/E(ttm) only.
MNK' s P/E(ttm) Range Over the Past 10 Years
Min: 13.62  Med: 42.33 Max: 73.52
Current: 15.34
13.62
73.52
Forward P/E 6.80
MNK's Forward P/E is ranked higher than
88% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. MNK: 6.80 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.91
MNK's PE(NRI) is ranked higher than
70% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.81 vs. MNK: 18.91 )
Ranked among companies with meaningful PE(NRI) only.
MNK' s PE(NRI) Range Over the Past 10 Years
Min: 16.81  Med: 87.75 Max: 416.74
Current: 18.91
16.81
416.74
P/B 1.33
MNK's P/B is ranked higher than
78% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. MNK: 1.33 )
Ranked among companies with meaningful P/B only.
MNK' s P/B Range Over the Past 10 Years
Min: 1.17  Med: 2.24 Max: 3.59
Current: 1.33
1.17
3.59
P/S 2.08
MNK's P/S is ranked higher than
61% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. MNK: 2.08 )
Ranked among companies with meaningful P/S only.
MNK' s P/S Range Over the Past 10 Years
Min: 1.11  Med: 2.44 Max: 4.69
Current: 2.08
1.11
4.69
POCF 6.66
MNK's POCF is ranked higher than
86% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. MNK: 6.66 )
Ranked among companies with meaningful POCF only.
MNK' s POCF Range Over the Past 10 Years
Min: 5.91  Med: 14.71 Max: 45.78
Current: 6.66
5.91
45.78
EV-to-EBIT 21.90
MNK's EV-to-EBIT is ranked lower than
54% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. MNK: 21.90 )
Ranked among companies with meaningful EV-to-EBIT only.
MNK' s EV-to-EBIT Range Over the Past 10 Years
Min: -919.8  Med: 33.30 Max: 241.3
Current: 21.9
-919.8
241.3
EV-to-EBITDA 9.32
MNK's EV-to-EBITDA is ranked higher than
78% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. MNK: 9.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.9  Med: 19.40 Max: 45.1
Current: 9.32
8.9
45.1
Current Ratio 1.73
MNK's Current Ratio is ranked lower than
66% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MNK: 1.73 )
Ranked among companies with meaningful Current Ratio only.
MNK' s Current Ratio Range Over the Past 10 Years
Min: 1.73  Med: 2.35 Max: 2.86
Current: 1.73
1.73
2.86
Quick Ratio 1.31
MNK's Quick Ratio is ranked lower than
66% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. MNK: 1.31 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s Quick Ratio Range Over the Past 10 Years
Min: 1.31  Med: 1.73 Max: 2.41
Current: 1.31
1.31
2.41
Days Inventory 80.97
MNK's Days Inventory is ranked higher than
69% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. MNK: 80.97 )
Ranked among companies with meaningful Days Inventory only.
MNK' s Days Inventory Range Over the Past 10 Years
Min: 62.36  Med: 71.89 Max: 96.82
Current: 80.97
62.36
96.82
Days Sales Outstanding 54.00
MNK's Days Sales Outstanding is ranked higher than
69% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. MNK: 54.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.82  Med: 66.36 Max: 68.48
Current: 54
59.82
68.48
Days Payable 28.60
MNK's Days Payable is ranked lower than
87% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. MNK: 28.60 )
Ranked among companies with meaningful Days Payable only.
MNK' s Days Payable Range Over the Past 10 Years
Min: 30.21  Med: 32.51 Max: 37.41
Current: 28.6
30.21
37.41

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.86
MNK's Price/Median PS Value is ranked higher than
75% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. MNK: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
MNK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.49  Med: 1.01 Max: 1.79
Current: 0.86
0.49
1.79
Earnings Yield (Greenblatt) (%) 4.56
MNK's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MNK: 4.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 2.40 Max: 4.8
Current: 4.56
0.4
4.8

More Statistics

Revenue (TTM) (Mil) $3,404
EPS (TTM) $ 4.01
Beta0.80
Short Percentage of Float12.79%
52-Week Range $50.90 - 132.60
Shares Outstanding (Mil)109.33

Analyst Estimate

Sep16 Sep17 Sep18
Revenue (Mil $) 3,726 3,823 3,923
EPS ($) 7.87 8.91 9.81
EPS without NRI ($) 7.87 8.91 9.81
EPS Growth Rate
(3Y to 5Y Estimate)
19.41%
» More Articles for MNK

Headlines

Articles On GuruFocus.com
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
John Paulson Keeps Gold, Buys Drug Manufacturers Nov 17 2015 
Pioneer Investments Adds to Stakes in Hartford Financial Group, Reynolds American Nov 13 2015 
Andreas Halvorsen Buys AIG, Google, 3 More as Top New Stocks May 29 2015 
Only Buy Luxury At A Deep Discount Apr 01 2015 
Mallinckrodt Has Brighter Days Going Ahead Mar 10 2015 
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Dumb Investment of the Week: Mallinckrodt PLC Jul 17 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 

More From Other Websites
5 Health Care Stocks Whose Charts Tell You to Wait to Buy May 26 2016
5 Health Care Stocks John Paulson Is Betting On in 2016 May 24 2016
Mallinckrodt Donates 250,000 Drug Deactivation Systems to ACT Missouri to Support Fight Against... May 23 2016
Trending Now: MNK May 23 2016
How Mallinckrodt’s Specialty Brands Performed in 2Q16 May 20 2016
ETF’s with exposure to Mallinckrodt Plc : May 19, 2016 May 19 2016
Mallinckrodt plc to Change Fiscal Year May 18 2016
MALLINCKRODT PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year May 18 2016
Mallinckrodt plc to Change Fiscal Year May 18 2016
Trader's Notebook: Mixing Coffee With Oil May 18 2016
Mallinckrodt Plc breached its 50 day moving average in a Bullish Manner : MNK-US : May 18, 2016 May 18 2016
The short seller who took down Valeant went on TV to explain why he has invested in it, and ended up... May 17 2016
Andrew Left Challenges Mallinckrodt to Do Proper Study of Its Main Drug May 17 2016
Mallinckrodt Is Robbing From the Healthcare System, Says Andrew Left May 17 2016
Mallinckrodt Is Robbing From the Health Care System, Says Andrew Left May 17 2016
Short seller buys Valeant May 17 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rare Cause of... May 17 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rare Cause of... May 17 2016
Mallinckrodt Is Robbing From the Healthcare System, Says Left May 17 2016
Mallinckrodt responds to Citron May 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)